Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab consolidation after R-CHOP in high-risk diffuse large B-cell lymphoma
NL-OMON52540Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by HOVON. Primary endpoint: Disease-free survival. Started Sep 2018; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON52540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52540.